Tom Bartlett
Verified
As seen in:
The Atlantic,
Apple Podcasts,
Medium,
The Guardian,
Yahoo Canada,
Aol,
Los Angeles Times,
The Atlantic Daily Newsletter,
WIRED Magazine,
POLITICO,
Stuff.co.nz
and
staff writer @theatlantic. signal: bartlett.85
Get in touch with Tom
Contact Tom, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Tom Bartlett’s Journalist Portfolio
See all 21 portfolio items →
The University of Austin Has Raised Eyebrows -- and Lots of Money
Articles
Page 3
CITYAM.COM WEDNESDAY 12 AUGUST 2026 | NEWS | 03 NHS data casts fresh light on Palantir row SASKIA KOOPMAN INTERNAL NHS data indicates that Palantir’s hospital discharge tool cut delays by as much as 28 per cent, City AM understands, challenging recent reports from critics of the tech giant that it had made “no noticeable improvement” to the healthcare system’s efficiency.
The Peptide Gold Rush Is Coming
BPC-157 is rumored to heal almost anything: a sore shoulder, a bum knee, a pulled hamstring, ulcerative colitis. Maybe even traumatic brain injuries and multiple sclerosis, too. The drug—part of a class called peptides—has been around for decades. But it has recently experienced a surge in popularity, thanks in part to great peptide publicity from influencers, podcasters, and Robert F. Kennedy Jr., the secretary of health and human services. Thousands of Americans are taking it.
The White House’s MAHA Gatekeeper
The world’s most popular podcaster, Joe Rogan, reached out privately in April to the world’s most powerful man, Donald Trump, to discuss the healing power of ibogaine, a psychedelic made from the root bark of a Central African shrub that researchers are studying as a treatment for addiction and trauma. Trump responded by text, “‘Sounds great. Do you want FDA approval?
Actions
Get in touch with Tom
Contact Tom, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack